Accessibility Menu
Agentix logo

Agentix(OTC) AGTX

Current Price$0.02
Market Cap$801.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-98%
1 Year-32%
1 Month+18%
Agentix last closing stock price
MetricPriceDate
Last closeUSD 0.022026-07-16
Agentix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.022026-06-30
1 month+17.65%USD 0.022026-06-16
3 month-54.44%USD 0.042026-04-13
Year to date-46.67%USD 0.042025-12-31
1 year-32.09%USD 0.032025-07-16
3 year-71.43%USD 0.072023-06-14
5 year-97.75%USD 0.892021-07-16
Since inception-99.34%USD 3.042020-06-10

Agentix Financials at a Glance

Market Cap

$801.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$485.64K

EPS (TTM)

-$0.01

P/E Ratio

-1.65

Dividend

$0.00

Beta (Volatility)

0.09 (Low)

Price

$0.02

Volume

1

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.01 - $0.06

Estimated Earnings Date

Feb 16, 2026

AGTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Agentix

Agentix develops medicines for people with obesity and diabetes. Its products aim to help manage weight and blood sugar. These medicines are still being tested and are not yet sold.

What’s in the Agentix Toolbox?

  • AGTX-2004: A medicine in development for obesity and type 2 diabetes; not yet generating revenue.
  • AGTX-2003: A medicine in development for obesity and fatty liver disease; also pre-revenue.

Growth and Expansion: The Agentix Adventure

  • No acquisitions or partnerships reported since incorporation in 2013.
  • Product pipeline expanded to include AGTX-2003 and AGTX-2004 by 2024.
  • No commercial launches or global market entries as of June 2025.

What Makes Agentix Stand Out?

Agentix focuses on new medicines for metabolic diseases, using a unique approach that targets specific body receptors. The company aims to reduce side effects by acting outside the brain. All resources go into research, with no commercial sales yet.

Five Things You Need to Know

  • Agentix reported $0 revenue for Q1 2024 and previous two years.
  • Net loss was $401,135 in Q1 2024, up 143.6% from Q1 2023.
  • Cash was $4,412 as of June 30, 2025, with negative working capital.
  • R&D expenses rose to $100,000 in Q2 2025, compared to $55,501 in Q2 2024.
  • Company relies on short-term debt and related party loans for funding.

Bottom Line

Agentix remains a research-focused company with no product sales. Its future depends on continued funding and successful medicine development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Rehan Huda

Website

www.agentixcorp.com

Headquarters

Dana Point, CA 92629, US

AGTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

14.09%

Return on Capital

N/A

Return on Assets

-62987.81%

Earnings Yield

-60.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$801.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.07M

Volume

1

Avg. Volume

10.77K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$445.19K

EBITDA

-$445.19K

Operating Cash Flow

-$108.53K

Capital Expenditure

$0.00

Free Cash Flow

-$108.53K

Cash & ST Invst.

$771.00

Total Debt

$353.45K

Agentix Performance Analysis

Agentix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Agentix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30N/A
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Agentix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -0.04-44.2%
20242024-03-31USD -0.01-58.3%
20252025-03-31USD -0.01-2.7%
20262026-03-31USD -0.01-14.8%
Agentix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-2.2%
Q22025-09-3021.7%
Q32025-12-3144.4%
Q42026-03-31110.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$801.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$267.10K

N/A

Employees

3

N/A

Net Income

-$77.11K

+57.6%

EBITDA

-$54.29K

+68.5%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$771.00

-82.8%

Total Debt

$353.45K

+45.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$353.45K

+45.5%

Return on Assets

-629.88%

N/A

Return on Invested Capital

12.38%

N/A

Free Cash Flow

$14.78K

+134.3%

Operating Cash Flow

$14.78K

+134.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGNPFGrey Matters Health Inc.
$0.30+2.24%
NBCONeon Bloom, Inc.
$0.01+0.00%
APLIFAppili Therapeutics Inc
$0.01+0.00%
HESGHealth Sciences Group, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.28+0.11%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$45.95+0.03%
BMNRBitmine Immersion Technologies
$17.65+0.12%

Questions About AGTX

What is the current price of Agentix?

Agentix is trading at $0.02 per share.

What is the 52-week range for Agentix?

Over the past 52 weeks, Agentix has traded between $0.01 and $0.06.

How much debt does Agentix have?

As of the most recent reporting period, Agentix reported total debt of $353.45K.

How much cash does Agentix have on hand?

Agentix reported $771.00 in cash and cash equivalents in its most recent financial results.

What is Agentix’s dividend yield?

Agentix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services